{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:13:37Z","timestamp":1760346817436,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejso.2019.11.510","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T09:19:30Z","timestamp":1575278370000},"page":"918-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thick melanomas without lymph node metastases: A forgotten group with poor prognosis"],"prefix":"10.1016","volume":"46","author":[{"given":"M.A.","family":"El Sharouni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Witkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejso.2019.11.510_bib1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejso.2019.11.510_bib2","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA A Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ejso.2019.11.510_bib3","first-page":"18","article-title":"A\u00a0global review of melanoma follow-up guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"author":"The Dutch Melanoma Workgroup","key":"10.1016\/j.ejso.2019.11.510_bib4"},{"issue":"19","key":"10.1016\/j.ejso.2019.11.510_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ejso.2019.11.510_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ejso.2019.11.510_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2019.11.510_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2019.11.510_bib9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jid.2016.03.014","article-title":"Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study","volume":"136","author":"Youlden","year":"2016","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.ejso.2019.11.510_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.1134","article-title":"Comparison of survival between patients with single vs multiple primary cutaneous melanomas","author":"El Sharouni","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejso.2019.11.510_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2016.08.014","article-title":"Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival","volume":"67","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2019.11.510_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/sim.1597","article-title":"Regression models for relative survival","volume":"23","author":"Dickman","year":"2004","journal-title":"Stat Med"},{"issue":"15","key":"10.1016\/j.ejso.2019.11.510_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2016.71.9393","article-title":"Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis","volume":"35","author":"Haydu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2019.11.510_bib15","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bjd.17145","article-title":"Eighth American Joint committee on cancer (AJCC) melanoma classification: what about stage IIC?","volume":"179","author":"Brancaccio","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ejso.2019.11.510_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.24635","article-title":"Clinical prognostic markers in stage IIIC melanoma","volume":"116","author":"Madu","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2019.11.510_bib17","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"10.1016\/j.ejso.2019.11.510_bib18","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2019.11.510_bib19","article-title":"Guidelines of care for the management of primary cutaneous melanoma","author":"Swetter","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejso.2019.11.510_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update","volume":"36","author":"Wong","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319314611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319314611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:33:49Z","timestamp":1760060029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319314611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0748798319314611"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.510","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thick melanomas without lymph node metastases: A forgotten group with poor prognosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}